Chemical Structure : NRPa-308
CAS No.:
717863-53-1
NRPa-308
(NRPa 308)
Catalog No.: PC-21447Not For Human Use, Lab Use Only.
NRPa-308 is a neuropilin-1 (NRP-1) antagonist, inhibits the VEGF-A165/NRP-1 binding with IC50 of 42 uM, exerts in vitro anti-angiogenic activity.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
NRPa-308 is a small molecule neuropilin-1 (NRP-1) antagonist, inhibits the VEGF-A165/NRP-1 binding with IC50 of 42 uM, exerts in vitro anti-angiogenic activity.
NRPa-308 exhibits cellular activity with IC50 of 0.5 uM on a human aggressive and metastatic estrogenR−/progesteroneR−/Her2- breast cancer cell line (MDA-MB-231).
NRPa-308 dramatically inhibits tubulogenesis for HUVEC tubule formation in a collagen gel under VEGF-A165 stimulation.
NRPa-308 (50 mg/kg) improves the median survival and reduces the tumour growth on mice xenografted with human breast cancer cells (MDA-MB-231), does not exert visible acute toxicity.
Physicochemical Properties
|
M.Wt
|
424.52
|
|
Formula
|
C23H24N2O4S
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20°C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80°C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
N-(2-ethoxyphenyl)-4-methyl-3-(N-(p-tolyl)sulfamoyl)benzamide
|
References
1. Wang-Qing Liu, et al. Cancer Lett. 2018 Feb 1:414:88-98.
Contact Us
sales@probechem.com
